Check out the latest news and media coverage from SML Biopharm.
SML Biopharm has signed an MOU with Cha Vaccine Institute for joint development of mRNA-based vaccines and therapeutics.
Read MoreSML Biopharm has signed an MOU with Cha Vaccine Institute for joint development of mRNA-based vaccines and therapeutics.
Maeil Business Newspaper featured SML Biopharm's mRNA therapeutics development progress and future plans.
SML Biopharm has signed an MOU with French biotech company Affilogic for Nanofitin-based targeted drug development.
Korea Economic Daily reported on SML Biopharm's global partnership network expansion.
SML Biopharm's mRNA-based personalized cancer vaccine has entered the preclinical stage.
SML Biopharm is recruiting researchers and management support staff for the first half of 2025.
SML Biopharm researchers participated as the only invited speaker from a Korean company at the European mRNA Summit in Frankfurt, Germany.
SML Biopharm signed an MOU with China's Probio for comprehensive cooperation in mRNA development, production, and clinical research.
Strategic partnership signed with Switzerland's CATUG for mRNA technology development and commercialization.
SML Biopharm has been selected for the MOHW Infectious Disease Prevention R&D Project, receiving total funding of 2.05 billion KRW over 3 years.
BioSpectator provided detailed coverage of SML Biopharm's SFTS antibody therapeutics development.
SML Biopharm has acquired the usage rights for SFTS virus neutralizing antibody sequences from AI BIO.
